Natera Stock Hits 52-Week High on Record Signatera Test Volumes

Natera Inc. (NASDAQ:NTRA) shares reached a new 52-week high this week, propelled by company disclosures of record demand and accelerating momentum for its flagship Signatera cancer-monitoring test.

Signatera Growth Accelerates

Speaking at the 2026 Global Healthcare Conference on September 16, Natera executives revealed that sequential unit additions for Signatera hit approximately 34,000. This figure significantly surpasses the company's previous record of 25,000 set in the first quarter, signaling accelerating adoption of the test.

The company also reported a steady increase in the average selling price (ASP), which has climbed by $25 for three consecutive quarters to reach about $1,275 per test. Management reiterated its long-term ASP target of $2,000 and maintained its full-year revenue guidance with a midpoint around $2.9 billion.

Ad

Market Performance and Analyst Views

The positive operational update pushed Natera's stock to a fresh 52-week high of $347.10 before closing at $345.34 on September 17. The rally has lifted the company's market capitalization to nearly $49.2 billion.

This performance builds on a strong prior quarter in which Natera's revenue grew 37.7% year-over-year to $752.8 million. In response to the growth story, Guggenheim raised its price target to $360 with a Buy rating. The broader analyst consensus target of approximately $330.83 now sits below the stock's current trading level, indicating that recent price action has outpaced some market expectations.